United States SGLT2 Inhibitors Market was valued at USD 1.8 Billion in 2022 and is projected to reach USD 5.2 Billion by 2030, growing at a CAGR of 16.9% from 2024 to 2030.
The US SGLT2 inhibitors market is experiencing rapid growth, driven by an increasing demand for effective treatments for type 2 diabetes and heart failure. These inhibitors have gained significant attention in the medical community due to their dual therapeutic effects, not only lowering blood sugar levels but also providing heart and kidney protection. As the healthcare industry continues to prioritize chronic disease management, the need for advanced pharmaceutical solutions like SGLT2 inhibitors is more prominent than ever before.
SGLT2 inhibitors, such as empagliflozin, dapagliflozin, and canagliflozin, work by blocking the sodium-glucose co-transporter 2 in the kidneys, preventing glucose reabsorption and promoting its excretion through urine. This mechanism helps control blood glucose levels in patients with diabetes while reducing the risk of cardiovascular events and renal complications. Given the rising prevalence of diabetes and heart disease in the US, there is a significant market demand for these innovative therapies.
The healthcare industry's requirement for SGLT2 inhibitors goes beyond just managing diabetes. With cardiovascular diseases being a leading cause of death in the US, the adoption of SGLT2 inhibitors as an adjunct treatment for heart failure and chronic kidney disease has become a game-changer. Pharmaceutical companies are ramping up production, and research into new SGLT2 inhibitors continues to expand, aiming to improve patient outcomes in multiple therapeutic areas.
Additionally, the pharmaceutical sector is continuously looking for ways to refine these inhibitors’ effectiveness. As a result, SGLT2 inhibitors are now being explored for use in conditions like obesity and polycystic kidney disease. The broadening scope of these treatments highlights the versatile nature of SGLT2 inhibitors and their critical role in modern medicine.
In summary, the SGLT2 inhibitors market in the US is poised for significant expansion, driven by the increasing demand from both patients and healthcare professionals. The industry's growing recognition of the value these drugs bring in managing multiple chronic conditions ensures that their presence in the market will only continue to strengthen.
Get an In-Depth Research Analysis of the US SGLT2 Inhibitors Market Size And Forecast [2025-2032]
Â
AstraZeneca
Hengrui Medicine
Johnson and Johnson
Kelun Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Hansoh Pharmaceutical Group
Orifarm
Starpharma
Sandoz
Bristol-Myers Squibb
Boehringer Ingelheim
Merck
Â
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the US SGLT2 Inhibitors Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the US SGLT2 Inhibitors Market
Dapagliflozin
Empagliflozin
Canagliflozin
Ergoloid mesylates (including new generation compounds)
Others (e.g., Ipragliflozin)
Type 2 Diabetes Mellitus
Heart Failure
Chronic Kidney Disease
Weight Management
Hypertension
Oral
Injectable
Hospital pharmacies
Retail pharmacies
Online pharmacies
Clinics
Others (e.g., specialty pharmacies)
Adults (aged 18-65)
Seniors (aged 65 and above)
Pediatric populations (aged 0-17)
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ SGLT2 Inhibitors Market Research Analysis
1. Introduction of the US SGLT2 Inhibitors Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. US SGLT2 Inhibitors Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. US SGLT2 Inhibitors Market, By Type
6. US SGLT2 Inhibitors Market, By Application
7. US SGLT2 Inhibitors Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. US SGLT2 Inhibitors Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading US Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/